Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Got story updates? Submit your updates here. ›

Alto Neuroscience, a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders, announced that members of its management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.

Why it matters

Alto's participation in this prominent industry event highlights the company's commitment to advancing its pipeline of novel drug candidates for mental health conditions. As a clinical-stage biopharmaceutical firm, Alto's presence at the Stifel Virtual CNS Forum provides an opportunity to share updates on its Precision Psychiatry Platform and engage with key stakeholders in the central nervous system (CNS) therapeutics space.

The details

The virtual fireside chat presentation will be accessible via a live webcast on Alto's website, and a replay will be available following the event. Alto's Precision Psychiatry Platform leverages brain biomarkers, EEG activity, neurocognitive assessments, and wearable data to identify patients more likely to respond to the company's drug candidates, which are in clinical development for conditions like depression and schizophrenia.

• The Stifel 2026 Virtual CNS Forum will take place on March 17, 2026.
• Alto's virtual fireside chat presentation is scheduled for 12:00pm ET on March 17, 2026.

What’s next

Alto will make the webcast of its virtual fireside chat presentation available on its website following the Stifel 2026 Virtual CNS Forum.